Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Their appointment was initiated by the outgoing board of directors. The four new members will bring many years of experience in the biotech and pharmaceutical industry, especially in research and...
-
Focus on the discovery of next-generation LRRK2 inhibitors to unlock novel biological mechanisms of action and advance new treatment options YONGIN, South Korea, April 15, 2025 – 1ST Biotherapeutics,...
-
Wichtiger Meilenstein zur Vorbereitung des europäischen Markteintritts und Beleg des Engagements für Qualität Los Angeles, USA - 9. April 2025 - ANEUVO, ein Pionier auf dem Gebiet der Entwicklung...
-
First-ever use of Ebenbuild’s Twinhale technology in idiopathic pulmonary fibrosis lung modelsTrial results published in Nature Communications Munich, Germany – April 9, 2025 -- Ebenbuild, a company...
-
Presentation by Prof. Anand Deva highlights 87% breast volume retention and low complication rate in one-year patient follow-upSuccessful vascularization and vessel formation in two-year follow-up...
-
Findings highlight underexplored role of intestinal brush border in protein digestion, and its vulnerability to inflammatory damage in celiac disease Review discusses potential benefits of...
-
One-year follow-up data confirm favorable safety profile of BellaSeno´s scaffolds compared to silicone implantsCompany plans expansion to primary breast augmentation and lumpectomy Leipzig, Germany/...
-
- tiakis and Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH) Kiel, Germany, January 8, 2025 – tiakis Biotech AG, a clinical-stage biopharmaceutical company...
-
Novel paradigm for therapeutics based on RNA splicing modulationLead program in Huntington’s disease Denmark – Odense – 07/01/2025 – Inverna Therapeutics, a novel Danish biotech company at the...
-
- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...